Evaluating the safety profile of calcineurin inhibitors: cancer risk in patients with systemic lupus erythematosus from the LUNA registry—a historical cohort study

Evaluating the safety profile of calcineurin inhibitors: cancer risk in patients with systemic lupus erythematosus from the LUNA registry—a historical cohort study

Abstract Background Previous studies have shown conflicting evidence regarding the incidence of cancer in patients with systemic lupus erythematosus (SLE) compared with that in healthy individuals. Calcineurin inhibitors (CNIs) such as cyclosporine and tacrolimus have been widely used to treat SLE;...

Full description

Bibliographic Details
Main Authors: Kunihiro Ichinose, Shuntaro Sato, Takashi Igawa, Momoko Okamoto, Ayuko Takatani, Yushiro Endo, Sosuke Tsuji, Toshimasa Shimizu, Remi Sumiyoshi, Tomohiro Koga, Shin-ya Kawashiri, Naoki Iwamoto, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Nobuyuki Yajima, Ken-Ei Sada, Yoshia Miyawaki, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Shuzo Sato, Michio Fujiwara, Atsushi Kawakami
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Arthritis Research & Therapy
Subjects:
Systemic lupus erythematosus
Calcineurin inhibitors
Cancer
Propensity score
IPW
Online Access:https://doi.org/10.1186/s13075-024-03285-x

Internet

https://doi.org/10.1186/s13075-024-03285-x

Similar Items